Home/Pipeline/Treg-directed therapy for ALS

Treg-directed therapy for ALS

Amyotrophic Lateral Sclerosis (ALS)

Pre-clinicalActive

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Pre-clinical

Status

Active

Company

Iltoo Pharma

About Iltoo Pharma

Iltoo Pharma is a private, preclinical-stage biotech based in Paris, developing novel biologics targeting regulatory T cells to restore immune tolerance in autoimmune and inflammatory diseases. The company's leadership features a world-class Scientific Advisory Board with deep expertise in immunology and clinical development, and its strategy is built on valuable partnerships. While currently pre-revenue, Iltoo is targeting high-unmet-need conditions like ALS, positioning itself in the rapidly evolving field of immunomodulation.

View full company profile

Therapeutic Areas

Autoimmune Diseases Neuroimmune Diseases Inflammatory Diseases Amyotrophic Lateral Sclerosis

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
NG CELL	NeuroGenesis Bio	Phase 2	Active